Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Linking the microbiome to CAR-T cell responses

The composition of the intestinal microbiome may predict clinical outcomes of CAR-T cell therapy for lymphoma, which could inform microbiota-based intervention strategies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Evaluating the effects of the intestinal microbiome on outcomes of CAR-T cell therapy in patients with lymphoma.

References

  1. Peled, J. U. et al. New Engl. J. Med. 382, 822–834 (2020).

    Article  CAS  PubMed  Google Scholar 

  2. Smith, M. et al. Nat. Med. 28, 713–723 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gopalakrishnan, V. et al. Science 359, 97–103 (2018).

    Article  CAS  PubMed  Google Scholar 

  4. Routy, B. et al. Science 359, 91–97 (2018).

    Article  CAS  PubMed  Google Scholar 

  5. Stein-Thoeringer, C. K. Nat. Med. https://doi.org/10.1038/s41591-023-02234-6 (2023).

    Article  PubMed  Google Scholar 

  6. Weber, D. et al. Biol. Blood Marrow Transplant 23, 845–852 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. van Lier, Y. F. et al. Sci. Transl. Med. 12, eaaz8926 (2020).

    Article  PubMed  Google Scholar 

  8. Davar, D. et al. Science 371, 595–602 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marcela V. Maus.

Ethics declarations

Competing interests

Z.D. receives research support from Incyte, Corp., Regimmune, Corp and Taiho Oncology, Inc. and has received consulting fees from Kadmon Corp., Omeros Corp., Incyte, Corp., MorphoSys AG, Inhibrx and PharmaBiome AG. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab) and University of Pennsylvania (some licensed to Novartis). M.V.M. receives Grant/Research support from: Kite Pharma. M.V.M. has served as a consultant for multiple companies involved in cell therapies. M.V.M. holds Equity in 2SeventyBio, Century Therapeutics, Neximmune, Oncternal and TCR2. M.V.M. is on the Board of Directors of 2Seventy Bio.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DeFilipp, Z., Maus, M.V. Linking the microbiome to CAR-T cell responses. Nat Med 29, 785–786 (2023). https://doi.org/10.1038/s41591-023-02272-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02272-0

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer